Lyka Labs Ltd.

NSE: LYKALABS BSE: 500259 SECTOR: Pharmaceuticals & Drugs  7379   16   1

164.00
+7.80 (4.99%)
NSE: Today, 04:02 PM

Price Summary

Today's High

₹ 164

Today's Low

₹ 164

52 Week High

₹ 156.2

52 Week Low

₹ 19.05

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

470.52 Cr.

Enterprise Value

625.72 Cr.

No. of Shares

2.87 Cr.

P/E

10.09

P/B

8.76

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  18.73

CASH

6.53 Cr.

DEBT

161.73 Cr.

Promoter Holding

20 %

EPS (TTM)

₹  16.25

Sales Growth

52.82%

ROE

-124.71 %

ROCE

4.45%

Profit Growth

73.89 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year52.82%
3 Year14.31%
5 Year1.69%

Profit Growth

1 Year73.89%
3 Year-12.67%
5 Year-224.57%

ROE%

1 Year-124.71%
3 Year-72.63%
5 Year-46.19%

ROCE %

1 Year4.45%
3 Year-5.71%
5 Year-1.99%

Debt/Equity

36.6799

Price to Cash Flow

81.82

Interest Cover Ratio

0.280106289721674

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 20 17.95
Jun 2021 19.88 26.76
Mar 2021 19.88 26.76
Dec 2020 19.88 26.76
Sep 2020 19.88 26.76
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -24.7937280310154 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 777.794790920706.

 Limitations

  • The company has shown a poor profit growth of -12.6676165235056% for the Past 3 years.
  • The company has shown a poor revenue growth of 14.3134426596035% for the Past 3 years.
  • Company has a poor ROE of -72.6340824402712% over the past 3 years.
  • Company has a poor ROCE of -5.7138634499577% over the past 3 years
  • Company has high Debt to Equity ratio of 36.6799.
  • Company has low Interest coverage ratio of 0.280106289721674.
  • Company has contingent liabilities of 40.847 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 12.9 18.91 17.82 43.47 65.02
Total Expenditure 10.41 14.31 12.36 13.66 20.81
Operating Profit 2.49 4.61 5.46 29.81 44.21
Other Income 0.41 0.4 0.85 0.53 0.86
Interest 6.47 6.53 6.31 6.89 5.53
Depreciation 2.04 2.05 1.95 2.05 2.09
Exceptional Items -0.09 0.36 -1.7 0 -2.04
Profit Before Tax -5.69 -3.21 -3.64 21.4 35.41
Tax 0.15 -0.15 -3.88 1.75 5.59
Profit After Tax -5.83 -3.07 0.23 19.65 29.81
Adjusted EPS (Rs) -2.03 -1.07 0.08 6.85 10.39

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 78.01 41.68 41.18 40.74 62.26
Total Expenditure 56.24 42.2 40.27 43.96 47.84
Operating Profit 21.77 -0.52 0.91 -3.22 14.43
Other Income 1.71 1.89 2.66 2.6 2.21
Interest 16.54 7.76 5.73 19.01 25.55
Depreciation 5.53 6.31 4.44 7.77 8.05
Exceptional Items -1.96 1.47 -0.51 -27.75 -1.43
Profit Before Tax -0.56 -11.22 -7.1 -55.15 -18.4
Tax -0.37 -0.38 -8.83 0.24 -3.94
Net Profit -0.19 -10.84 1.73 -55.39 -14.46
Adjusted EPS (Rs.) -0.08 -3.85 0.62 -19.31 -5.04

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 22.04 28.14 28.14 28.69 28.69
Total Reserves 51.57 68.64 70.46 -9.91 -24.28
Borrowings 35.48 4.71 78.8 125.69 151.06
Other N/C liabilities 1.29 1.45 -7.24 9.18 -3.07
Current liabilities 131.37 140.46 68.29 55.34 44.75
Total Liabilities 241.75 243.41 238.46 208.98 197.15
Assets
Net Block 86.27 81.16 76.23 101.65 95.34
Capital WIP 16.7 16.66 17.55 16.6 16.18
Intangible WIP 7.54 9.77 12.16 9.8 8.22
Investments 62.45 62.45 62.45 32.4 32.4
Loans & Advances 21.01 20.12 21.03 17.83 19.28
Other N/C Assets 0 0 0 0 0
Current Assets 47.79 53.24 49.03 30.7 25.74
Total Assets 241.75 243.41 238.46 208.98 197.15
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations -0.56 -11.22 -7.1 -55.15 -18.4
Adjustment 22.16 11.81 10.34 54.79 33.97
Changes in Assets & Liabilities -0.29 6.69 15.3 -11.85 -9.1
Tax Paid -1.2 -0.44 -0.22 0.77 -0.72
Operating Cash Flow 20.17 6.84 18.31 -11.45 5.75
Investing Cash Flow -5.25 -3.35 -2.94 0.13 0.13
Financing Cash Flow -15.2 -4.48 -15.76 19.61 -7.75
Net Cash Flow -0.28 -0.99 -0.38 8.28 -1.88

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 19.88 19.88 19.88 19.88 20.00
narendra ishwarlal... 4.88 4.88 4.88 4.88 4.88
narendra ishwarlal... 4.07 4.07 4.07 4.07 4.07
nehal narendra gan... 3.99 3.99 3.99 3.99 3.99
kunal narendra gan... 3.51 3.51 3.51 3.51 3.55
enai trading and i... - 3.42 3.42 3.42 3.46
enai trading and i... 3.42 - - - -
lyka animal health... - - - - 0.04
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 80.12 80.12 80.12 80.12 80.00
mayank jashwantlal... 6.98 6.98 6.98 8.13 6.98
shruti mayank shah 5.28 5.30 5.30 5.30 5.30
prasham mayank shah 5.23 5.23 5.23 5.23 5.23
cobra india (mauri... 3.50 3.50 3.50 3.50 2.07
amee parikh 3.40 3.40 3.40 3.40 3.40
dalal & broacha st... 2.79 - - - -
dalal & broacha st... - 2.78 2.78 2.79 -
dalal and broacha ... - - - - 2.79
girish gulati huf . - - - 2.00 1.10
shreyans jashwantl... 1.74 1.74 1.74 1.74 1.74
quant mutual fund ... - - - - 1.38
jamnotri impex pvt... - - - - 1.26
mayank jashwantlal... 1.05 1.05 1.05 - 1.10
pranay godha 1.05 1.05 1.05 1.05 1.05

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Lyka Labs Stock Price Analysis and Quick Research Report. Is Lyka Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lyka Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 5.7503 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lyka Labs has a Debt to Equity ratio of 36.6799 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lyka Labs , the EPS growth was 73.8945983465595 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lyka Labs has OPM of 23.168816150844 % which is a good sign for profitability.
     
  • ROE: Lyka Labs have a poor ROE of -124.707505875757 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Lyka Labs

X